Sitemap

Splash Page

Public

Issue No. 4 - Jan. 27, 2012
From One Competitive Market to Another: UC San Diego Stakes a Claim in Las Vegas
FDA Didn't Punish Duke for Failure to Seek Proper Regulatory Clearance for Three Trials
News Analysis: Trials Went On Despite FDA Statements
Issue No. 5 - Feb. 3, 2012
Issue No. 6
Planned Parenthood May Be Doing Harm By Selling Screening To Women Under 40
See The Cancer Letter on 60 Minutes: Deception at Duke
ODAC Votes to Nix Amgen's Drug Xgeva For New Prostate Cancer Indication
President Obama Proposes Flat Funding for NIH; And Realignment of Institutes' Budgets
Issue No. 7 - Feb. 17, 2012
FDA Relies on Early Importation, Fast Approval, and Early Reporting to Combat Shortages
Guest Editorial: FDA Must Address Economic Incentives to Resolve Drug Shortages Permanently
South Carolina Clinic, Anil Potti Part Ways
Issue No. 8 - Feb. 24, 2012
HHS Agency Says it has No Jurisdiction and No Cause to Act on Allegations
News Analysis: The Political Economy of Importations to Alleviate Cancer Drug Shortages
Importation is Remedy of Last Resort in Effort to Obtain Generic Injectables
Issue No. 9 - March 2, 2012
Issue No. 10 - March 9, 2012
In Legal Brawl, UPenn, Abramson Institute Say Former Director "Absconded" With Inventions
News Analysis: Filing Will Ignite Complex Litigation Costing Millions, With Uncertain Rewards
Issue No. 11 - March 16, 2012
The Philadelphia Story: How Surprise Filing by Abramson Spurred Penn to Follow Suit
Guest Editorial: Cancer From Fukushima? Is Sushi-Eating Over?
IOM Omics Committee Offers Blueprint to Prevent Other Duke-Style Disasters
Called "Unscrupulous" in Abramson Lawsuit, Thompson Calls Abramson a Rich Man Scorned
Issue No. 12 - March 23, 2012
Additional Level of Grant Review Proposed As NIH Prepares For Cost Cutting in 2013
Issue No. 13 - March 30, 2012
ODAC Votes for Marqibo Accelerated Approval; Two Sarcoma Drugs Pose Classic Question: How Much PFS Does it Take to Get a Nod?
As For-Profits Provide Phase I Studies Faster, NCI Seeks to Look Deeper, Learn More
Q & A with The Cancer Letter: Phase I Program Will Stress Correlative Studies For Small Biotech Firms, Says NCI's Doroshow
Issue 14 - April 6, 2012
The Cost of Healthcare How to Become a Urology Millionaire...Alas, One Little Problem—Overtreatment
Oncologists Don't Demand Increased Survival When Ordering Expensive Drugs, Survey Finds
Issue no. 15 - April 13, 2012
The Cancer Letter Special Issue, April 20, 2012
Senate Legislation Tackles Drug Shortages, Proposes Faster Approval For "Breakthroughs"
News Analysis: Generic Drug Industry's Efforts to Eliminate Shortages Raises Antitrust Law Questions
Richard Pazdur Waxes On Calumet City And Krebiozen
Issue No. 17 - April 27, 2012
Standard Procedures Discarded in Review Of $20 Million in Texas Funds For Project Led by Wife of MD Anderson President
Q&A: MD Anderson Provost Had No Say
Issue 21 - May 25, 2012
DePinho Apologizes For Investment Advice: On CNBC He Recommended A Firm He Founded
DePinho Seeks New Review of Incubator Proposal
Issue No. 22 - June 1, 2012
UT System Launches Probe of Submission Of Controversial MD Anderson Grant
Attendance Flags at Komen Flagship Race; D.C. Participation Drops by Nearly One-Third
Issue 23 - June 8, 2012
NCCN in Transition: New Strategy to Examine Role of Informatics, Revenue Sources and International Programs
UT Health System's Probe Finds Lapses At MD Anderson, CPRIT—But No Nepotism
Issue 24 - June 15, 2012
ODAC Nixes Sanofi's VTE Drug in 14-1 Vote, Setting High Bar For Adjunctive Therapies
News Analysis: Legislation on Drug Shortage Crisis Moves Toward Passage on Capitol Hill
Senate Increases NIH Funding for 2013, Rejects President's $200+ Million Increase For Program Evaluation Activities
Issue 25 - June 22, 2012
When Doctors Take Computers Home: Houston Burglary Points to Security Breach
Supreme Court Upholds Affordable Care Act In 5-4 Decision, Narrows Medicaid Provision
Guest Editorial: Supreme Court Decision on the ACA and What It Can Mean to Oncology
Issue no. 26 - June 29, 2012
Help Wanted: Varmus Irked by Having to Fill Jobs With Salaries NCI Can't Afford to Pay
Book Review: In Memoir Written to Avoid Doing Time, Disgraced Exec Reflects on BMS Heyday
Issue 27 - July 6,2012
Needed Enhancement or Unfunded Mandate? New NCI Program to Merge CCOP, NCCCP
Issue 28 - July 13, 2012
House Measure Would Eliminate AHRQ, Rescind PCORI, Cut Outcomes Research, And Halt NIH's Title 42 Hiring Program
Fallout Over PSA Guidance Continues— Specialty Groups Dissent, Congress Attacks
Conversation with The Cancer Letter: How ASCO's Guideline Differs—And Why
Issue No. 29 - July 20, 2012
FDA to Move Away From Central Radiology To Investigator Review In PFS Endpoint Trials
Conversation with The Cancer Letter: Statistician Lori Dodd Saw Research Question In the Midst of 2007 ODAC Debate Over Avastin
Issue No. 30 - July 27, 2012
Issue No. 31 - Aug. 3, 2012
DePinho Bets MD Anderson Credibility On His Cancer “Moon Shot” Program
A Year in Houston: DePinho Reflects on Plans, Conflicts, Controversies—and Lessons Learned
Issue No. 33 - Sept. 7, 2012
Suit Against Craig Thompson Settled As Company He Co-Founded Licenses "Newly Identified" Discoveries From UPenn
Earmarks for Research: "Recalcitrant" Cancers? Committee Rewrite Of Pancreatic Bill Raises New Questions
Issue 34 - Sept. 14, 2012
DePinho Seeks Broad Waiver From COI Policy To Cover Financial Ties With 12 Entities
As MD Anderson Targets Eight Cancers, Detailed War Plan Remains Under Wraps
White House Estimates 8.2 Percent Cut To NIH, NCI and FDA Budgets
Issue 35 - Sept. 21, 2012
Nobel Laureate Gilman Prepares to Leave The Texas Cancer Agency—Can it Survive?
Issue 36 - Sept. 28, 2012
NCCN's First Physician CEO: Carlson Pledges Broader Research, Policy Agendas
News Analysis: Industry's Accelerated Recovery Initiative May Push Manufacturers Toward Collusion
A Conversation with the new NCCN CEO, Robert Carlson
Issue no. 37 - Oct. 5, 2012
MD Anderson's Balance Sheet is Issue No. 1 For DePinho's "Moon Shots Program"
Blistering Resignation Letters Declare CPRIT Outside Mainstream of Science
Issue 38 - Oct. 12, 2012
Guest Editorial: Nobel Laureates Offer Simple Formula To Save CPRIT From "Infamy and Irrelevance"
A Misdirected Email: CPRIT Official Speaks of "New Regime" As Institute Denies Deepening Crisis
Issue no. 39 - Oct. 19, 2012
Politicians Applaud CPRIT's New Direction; UT Gives Waiver to MD Anderson's DePinho
Conversation with The Cancer Letter: UT System Vice Chancellor Shine Describes Rationale for Granting Waiver to DePinho
Komen Under Pressure: Charity Faces Money Woes, Attacks from Right
Issue no. 40 - Oct. 26, 2012
Conversation with The Cancer Letter - Sanofi: Zaltrap Price Reflects Competing Drugs In Second-Line Metastatic Colon Cancer
Unwanted Distinction: MSKCC Bars Zaltrap From Formulary, Triggering Debate Over Drug Pricing
Issue No. 41 - Nov. 2, 2012
Recalcitrant Cancer Bill Heading To Senate May Face Hold in the Lame Duck Session
Zaltrap Economics 101: The Pricing And Repricing of an Expensive Drug
Issue No. 43 - Nov. 16, 2012
Texas Agency Funded $11 Million Grant Without Peer Review; Official Resigns
NCCN, McKesson Form Partnership To Build Clinical Support Software
NCI Grant Funding: "Zone of Likelihood" Moves From 7th to 9th Percentile
Issue No. 44 - Nov. 30, 2012
CPRIT Executive Director Bill Gimson is Out As Scandal Grows, Investigations Begin
Turmoil in Texas: Margaret Kripke Comes out of Retirement To Become Chief Scientific Officer at CPRIT
Issue 46 - Dec. 14, 2012
The Raghavan Experiment: With $500 Million to Draw On, An Iconoclast Invents Rational Care for a Gigantic System
President Obama Signs Recalcitrant Cancers Bill
Issue 1 - Jan. 4, 2013
Sequestration Delayed for Two Months While Congress Debates Debt and Budgets
Blazing the Pathways: Informatics Platform Provides Foundation for "Center Without Walls"
Issue 2 - Jan. 11, 2013
Morale, Money Woes Hit MD Anderson
Issue No. 3 - Jan. 18, 2013
Guest Editorial: Omics Checklist Done, Now Make Business Model for Tests
Issue No. 6 - Feb. 8, 2013
NCI Unveils Checklist for Omics Studies
Conversation with The Cancer Letter Swain: “Shattering Impact on Cancer Enterprise”
Deep Budget Cuts Poised to Kick in March 1; Hill Insiders See Little Hope for Deal
Issue 7 - Feb. 15, 2013
NCI Spent $381.2 Million on PR from 2006-2012, Vastly Outspending Other NIH, FDA Units
Guest Editorial: Thoughts on Overusing Radiation in Medicine And Redeeming that Whole Body Scan Coupon
Issue 9 - March 1, 2013
Federal Budget Cuts Enacted March 1; HHS Agencies Grapple with Consequences
Collins Challenged Over NCI-Funded Research Linking Tea Party With Tobacco Companies
Issue 10 - March 8, 2013
Continuing Resolution Averts Shutdown; Locks in Sequestration Cuts for NIH, NCI
House Appropriator Claims NCI, NLM grants Funded Political Activity, Seeks OIG Probe
Issue 12 - March 22, 2013
Patient Care Emerges as Major Concern Following Sequestration Cuts to Medicare
City of Hope CEO Michael Friedman: Cancer Centers Must Adapt; "Not Losing Sleep" Over Sequestration
Issue 14 - April 5, 2013
Georgetown-Hackensack Consortium Plan Points to Rising Value of NCI Designation
In Myriad Case, the Supreme Court Hears About Tree Leaves, Baseball and Cookies
Issue 16 - April 19, 2013
CPRIT Likely to Get Funding For Two Years; DePinho Announces Austerity Measures
The Cancer Letter - Issue 20
NIH RPG Success Rate to Fall Further
“Of Sofas and Chairs” at MD Anderson: Official Seeks Protection from “Losers,” Explains Costly Interior Design Choices
The Cancer Letter - Issue 23
Advocacy Group Urges FDA to Sift Through Avastin Glioblastoma Data—Agency Accepts
Guest Editorial: Myriad Ruling Becomes a Textbook Case Of How Not To Manage a Patent Portfolio
FASEB: Focus on Research Funding, Not PR
MD Anderson Doctor Charged With Placing Ethylene Glycol In Colleague's Coffee
The Cancer Letter - Issue 24

Documents

Home

PayPal Subscription Cancellations
Kirsten Goldberg to Step Down As Cancer Letter Publisher
A note from Paul Goldberg, publisher of The Cancer Letter

Members-Only Content

Advertising

Who We Are

Home
Who We Are
Contact Us
Public